NHP 229
Alternative Names: NHP-229Latest Information Update: 28 Apr 2019
At a glance
- Originator New Haven Pharmaceuticals
- Class Zinc compounds
- Mechanism of Action Antacids
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(Adjunctive treatment) in USA (PO, Controlled release)
- 31 Mar 2016 Phase-I clinical trials in Gastro-oesophageal reflux (Adjunctive treatment) in USA (PO)
- 30 Jan 2014 Preclinical trials in Gastro-oesophageal reflux (adjunctive treatment) in USA (PO)